R
Rhythm Pharmaceuticals D
D
RYTM
86.350
USD
-1.88
(-2.13%)
Pre Open
Volume
5
EPS
-3
Div Yield
-
P/E
-28
Market Cap
5,896,413,118
Title: Rhythm Pharmaceuticals
Sector: Healthcare
Industry: Biotechnology
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.




